BioPharma, Pharma BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies By Frank Vinluan
BioPharma, Pharma BioNTech Turns to China Again for Cancer Drugs, Paying $70M to Partner on an ADC By Frank Vinluan
BioPharma, Pharma BioNTech and CEPI Team Up to Develop Mpox Vaccine That Meets 100-Day Goal By Frank Vinluan
BioPharma, Pharma At ASCO, BioNTech Shows Encouraging Data for Drug That Led to $200M Deal By Frank Vinluan
BioPharma, Pharma BioNTech Buys Into Hot Area of Cancer R&D, Paying $170M for 2 Drug Assets By Frank Vinluan
BioPharma, Pharma BioNTech Puts Up $200M to Partner With OncoC4 in Cancer Immunotherapy By Frank Vinluan
Artificial Intelligence, BioPharma BioNTech Dives Deeper Into Digital With £362M Buyout of AI Startup InstaDeep By Frank Vinluan
BioPharma, Pharma Pfizer, BioNTech seek FDA authorization for omicron-adjusted Covid-19 boosters By Frank Vinluan
BioPharma, Pharma Pfizer, BioNTech Covid-19 vaccine gets full FDA approval for adolescents By Frank Vinluan
BioPharma, Pharma CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents By Frank Vinluan
BioPharma, Pharma Aiming to make better mRNA vaccines, BioNTech strikes up alliance with Matinas By Frank Vinluan
BioPharma, Pharma BioNTech broadens its scope in cancer with Medigene cell therapy alliance By Frank Vinluan
BioPharma, Pharma Pfizer and BioNTech team up again, this time to develop an mRNA shingles vaccine By Frank Vinluan
BioPharma, Pharma BioNTech CEO: omicron is partial escape variant, but booster may restore protection By Frank Vinluan
